Peer Review reports
From: Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
| Original Submission | ||
|---|---|---|
| 24 Feb 2021 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| 21 Mar 2021 | Reviewed | Reviewer Report - Yasuhiro Kondoh |
| 31 Mar 2021 | Reviewed | Reviewer Report |
| 10 May 2021 | Author responded | Author comments - Ulrike Schmid |
| Resubmission - Version 3 | ||
| 10 May 2021 | Submitted | Manuscript version 3 |
| 12 May 2021 | Author responded | Author comments - Ulrike Schmid |
| Resubmission - Version 4 | ||
| 12 May 2021 | Submitted | Manuscript version 4 |
| 14 May 2021 | Author responded | Author comments - Ulrike Schmid |
| Resubmission - Version 5 | ||
| 14 May 2021 | Submitted | Manuscript version 5 |
| Publishing | ||
| 14 Jun 2021 | Editorially accepted | |
| 21 Jul 2021 | Article published | 10.1186/s12890-021-01598-0 |
You can find further information about peer review here.